Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew David Hellmann, Alexandra Snyder et al. · Science · 2015
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti-PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti-PD-1 therapy.
Cited by 7,793 works. doi:10.1126/science.aaa1348
Authors
- Naiyer A. Rizvi
- Matthew David Hellmann
- Alexandra Snyder
- Pia Kvistborg
- Vladimir Makarov
- Jonathan J. Havel
- William E. Lee
- Jianda D. Yuan
- Phillip Y.-P. Wong
- Teresa S. Ho
- Martin L. Miller
- Natasha Rekhtman
- Andre Luis Moreira
- Cameron Bruggeman
- Billel Gasmi
- Roberta Zappasodi
- Yuka Maeda
- Chris Sander
- Edward B. Garon
References
- Fast and accurate short read alignment with Burrows–Wheeler transform
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- A method and server for predicting damaging missense mutations
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- Integrative genomics viewer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients